ℹ️ Compiled from public regulatory records · Last regulator revision: April 30, 2026
Nadofaragene Firadenovec
Antineoplastic Cell and Gene Therapy
Sold as ADSTILADRIN
CA Health Canada
- Drug class
- Antineoplastic Cell and Gene Therapy
- Availability
- See label
- Routes
- Intravesical
- Markets covered
- 1
- Products on record
- 1
Overview
Nadofaragene Firadenovec is an active pharmaceutical ingredient in the Antineoplastic Cell and Gene Therapy group (L01XL). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 1 | April 30, 2026 |
CACanada· Health Canada
1 product
1 product on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [1].
Brands in Canada (1)
Sources & citations
- [1]Health Canada (DPD) · 02566680 · revised April 30, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.